Cannabinoid Type 2 Receptor System Modulates Paclitaxel-Induced Microglial Dysregulation and Central Sensitization in...

Area of Science:

• Neuroscience
• Pharmacology
• Immunology

Background:

• Paclitaxel chemotherapy can induce neuropathic pain by activating microglia and releasing pro-inflammatory mediators in the dorsal horn.
• This activation contributes to central sensitization and pain behaviors.
• Microglial dysregulation and overexpression of brain-derived neurotrophic factor (BDNF) are key pathological mechanisms.

Purpose of the Study:

• To investigate if MDA7, a selective cannabinoid type 2 (CB2) receptor agonist, can modulate paclitaxel-induced microglial activation.
• To determine if MDA7 suppresses BDNF overexpression in microglia.
• To evaluate MDA7's efficacy in attenuating paclitaxel-induced central sensitization and pain behavior.

Main Methods:

• Rats received paclitaxel to induce neuropathy.
• MDA7 or vehicle was administered before and after paclitaxel treatment.
• Behavioral tests assessed mechanical allodynia.
• Molecular studies analyzed microglial activation markers, cytokine expression (IL-6, IL-10), epigenetic factors (IRF8, P2X4), BDNF, and glutamate receptor subunits.

Main Results:

• Paclitaxel increased CB2 receptor expression, IL-6, IRF8, P2X4, CaMKIIα, p-CREB, ΔFosB, BDNF, GluR1, and NR2B, while decreasing K+-Cl- cotransporter, leading to mechanical allodynia.
• MDA7 treatment significantly attenuated these paclitaxel-induced molecular changes.
• MDA7 reduced IL-6 and increased IL-10 expression in microglia.

Conclusions:

• Paclitaxel induces microglial dysregulation and epigenetically upregulates BDNF expression, causing dorsal horn neuron sensitization and mechanical allodynia.
• The CB2 agonist MDA7 effectively alleviates these paclitaxel-induced pathological processes.
• MDA7 shows promise as an innovative therapeutic strategy for chemotherapy-induced neuropathic pain.